# EPI-326

Source: https://onco.cc/drugs/epi-326/  
OnCo record `epi-326` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

EPI-326 is an experimental bispecific antibody degrader from EpiBiologics, in phase 1 trials for EGFR-mutant non-small cell lung cancer and head and neck squamous cell carcinoma.

## Summary

EPI-326 is a bispecific antibody degrader (EpiTAC) from EpiBiologics. A tissue-selective bispecific antibody that degrades both wild-type and mutant EGFR in tumours while sparing EGFR in healthy tissue. Its furthest stage is phase 1, for EGFR-mutant non-small cell lung cancer and head and neck squamous cell carcinoma. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT07462377 recruiting; first patient dosed per company release of 19 April 2026. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: EPI-326
- Modality: Bispecific antibody degrader (EpiTAC)
- Mechanism: A tissue-selective bispecific antibody that degrades both wild-type and mutant EGFR in tumours while sparing EGFR in healthy tissue.

## Sources

- EpiBiologics: epibiologics.com: https://www.epibiologics.com/pipeline
- EpiBiologics: epibiologics.com: https://www.epibiologics.com/pipeline
- EpiBiologics: clinicaltrials.gov: https://clinicaltrials.gov/study/NCT07462377
- ClinicalTrials.gov: trials of EPI-326: https://clinicaltrials.gov/search?intr=EPI-326

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [EGFR](https://onco.cc/targets/egfr/)
- companies: [EpiBiologics](https://onco.cc/companies/epibiologics/)
- trials: [A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC](https://onco.cc/trials/nct07462377/)

---
JSON: https://onco.cc/api/v1/entities/epi-326.json